Prova en annan sökning
Symbol | Börs | Valuta | ||
---|---|---|---|---|
AMGN | NASDAQ | USD | Realtid | |
AMGN | Mexiko | MXN | Fördröjd | |
AMGN | BIVA | MXN | Fördröjd | |
AAMGN | Milano | EUR | Realtid | |
AMGN | TradeGate | EUR | Fördröjd | |
AMGN | Xetra | EUR | Fördröjd | |
AMGN | Frankfurt | EUR | Fördröjd | |
AMGNm | Buenos Aires | ARS | Fördröjd | |
AMGN34 | B3 | BRL | Fördröjd | |
AMGN | Wien | EUR | Realtid | |
AMGN | Lima | USD | Fördröjd |
AMGEN INC. är ett bioteknikföretag. Företaget upptäcker, utvecklar, tillverkar och levererar olika terapiprodukter för människor. Bolagets verksamhetssegment är terapiprodukter för människor. Portföljen av marknadsförda produkter inkluderar Neulasta (pegfilgrastim); erytropoesstimulerande medel (ESA) som Aranesp (darbepoetin alfa) och EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), och andra marknadsförda produkter som Vectibix (panitumumab), Nplate (romiplostim) och Corlanor (ivabradin). Företaget fokuserar sin forskning och utveckling på terapier för människor med allvarliga sjukdomar inom onkologi/hematologi, hjärt- och kärlsjukdomar, inflammationer, benhälsa, njurmedicin och neurovetenskap. Dess produkter i Phase III-program inkluderar Aranesp för myelodysplastiska syndrom; ENBREL för psoriasisartrit och reumatoid artrit remission; IMLYGIC för metastatiskt melanom och Kyprolis för multipelt myelom.
Namn | Ålder | Sedan | Titel |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Tyler E. Jacks | 62 | 2012 | Independent Director |
David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
Charles M. Holley | 66 | 2017 | Independent Director |
Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
Ellen J. Kullman | 68 | 2016 | Independent Director |
Robert A. Eckert | 70 | 2012 | Lead Independent Director |
Amy E. Miles | 57 | 2020 | Independent Director |
Wanda M. Austin | 70 | 2017 | Independent Director |
Greg C. Garland | 67 | 2013 | Independent Director |
Brian J. Druker | 68 | 2018 | Independent Director |
S. Omar Ishrak | 68 | 2021 | Independent Director |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Antoni Ribas | 57 | - | Member of Scientific Advisory Board of Oncology |
Peter Libby | 77 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Frank P. McCormick | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Michael V. Drake | 73 | 2022 | Independent Director |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Mary E. Klotman | - | 2024 | Director |
George Georgiou | 65 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
Ronald M. Evans | 75 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Robert Tjian | 75 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Fabrice Andre | - | - | Member of Scientific Advisory Board of Oncology |
Är du säker på att du vill blockera %USER_NAME%?
Genom att blockera kan du och %USER_NAME% inte se varandras inlägg på Investing.com.
%USER_NAME% lyckades läggas till i din Blockeringslista
Eftersom du precis avblockerat denna person måste du vänta 48 timmar för att kunna förnya blockeringen.
Jag anser att denna kommentar är:
Tack!
Rapporten har skickats till våra moderatorer för granskning